Research Article
Soluble CD163 as a Potential Biomarker in Systemic Sclerosis
Table 1
Clinical characteristics of SSc patients and controls.
| | SSc
() | Controls
() |
| | Age (years) | 58.9 ± 13.4 | 61.7 ± 13.9 | | Female, n (%) | 163 (80.2) | 43 (91.4) | | Disease duration (years) | 12 ± 8.9 | — | | Diffuse cutaneous subset, n (%) | 81/199 (40.7) | — | | Modified Rodnan skin score | 6.6 ± 7.7 | — | | Modified Rodnan skin score > 14, n (%) | 24/164 (17.7) | — | | ILD by HRCT, n (%) | 66/197 (33.5) | — | | Pulmonary hypertension, n (%) | 14/192 (7.3) | — | | History of digital ulcers (past or present), n (%) | 82/186 (44.1) | — | | PASP (mmHg) | 31.7 ± 9.2 | — | | PASP >30 mmHg, n (%) | 71/179 (39.6) | — | | PASP > 40 mmHg, n (%) | 22/179 (12.3) | — | | FVC (%pred.) | 95 ± 37 | — | | FVC < 75%pred., n (%) | 33/152 (21.7) | — | | DLCO (%pred.) | 64 ± 26 | — | | DLCO < 75%pred., n (%) | 104/153 (68) | — | | ACA positive, n (%) | 68/194 (35) | — | | Anti-Scl70 positive, n (%) | 61/194 (31.4) | — | | Anti-RNA polymerase III positive, n (%) | 12/194 (6.2) | — | | ESR (mm/h) | 18.7 ± 12.6 | — | | CRP (mg/L) | 5.5 ± 8.5 | — | | CRP > 10 mg/L, n (%) | 22/145 (15.2) | — | | Serum creatinine (μmol/L) | 72 ± 33 | — | | Serum creatinine > 120 μmol/L, n (%) | 5/132 (3.8) | — | | Ongoing prednisone therapy, n (%) | 66/172 (38%) | — | | Ongoing immunosuppressive therapy, n (%) | 67/164 (40.8) | — | | EScSG-AI | 1.4 ± 1.7 | — | | EScSG-AI > 3, n (%) | 23/157 (14.6) | — | | HAQ | 0.7 ± 0.6 | — |
|
|
Data are expressed as mean ± SD unless stated otherwise. SD = standard deviation; ACA = anticentromere antibodies; CRP = C-reactive protein; DLCO = diffusing capacity of the lung; EScSG-AI = European Scleroderma Study Group activity index; ESR = erythrocyte sedimentation rate; FVC = forced vital capacity; ILD = interstitial lung disease; HAQ = Health Assessment Questionnaire; HRCT = high-resolution computed tomography; PASP = pulmonary arterial systolic pressure.
|
